AA
KURA icon

ALPS Advisors’s Kura Oncology KURA Stock Holding History

ALPS Advisors’s Portfolio KURA Stock Details KURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$988K Buy
90,093
+18,187
+25% +$172K ﹤0.01% 707
2026
Q1 		$585K Buy
71,906
+459
+0.6% +$3.94K ﹤0.01% 674
2025
Q4 		$742K Buy
71,447
+32,465
+83% +$341K ﹤0.01% 646
2025
Q3 		$345K Sell
38,982
-7,678
-16% -$54.7K ﹤0.01% 938
2025
Q2 		$269K Buy
+46,660
New +$286K ﹤0.01% 958
2024
Q4 		– Sell
-58,695
Closed -$1.15M – 1023
2024
Q3 		$1.15M Sell
58,695
-708
-1% -$14.3K 0.01% 465
2024
Q2 		$1.22M Buy
59,403
+5,703
+11% +$117K 0.01% 421
2024
Q1 		$1.15M Buy
53,700
+3,221
+6% +$62.6K 0.01% 442
2023
Q4 		$726K Sell
50,479
-4,270
-8% -$42K 0.01% 552
2023
Q3 		$499K Buy
54,749
+4,441
+9% +$45.1K ﹤0.01% 598
2023
Q2 		$532K Buy
50,308
+5,215
+12% +$61.7K ﹤0.01% 604
2023
Q1 		$551K Sell
45,093
-1,180
-3% -$14.7K ﹤0.01% 580
2022
Q4 		$574K Buy
46,273
+9,806
+27% +$143K 0.01% 565
2022
Q3 		$498K Sell
36,467
-3,058
-8% -$47.2K ﹤0.01% 589
2022
Q2 		$724K Buy
+39,525
New +$569K 0.01% 523
2020
Q4 		– Sell
-71,775
Closed -$2.2M – 864
2020
Q3 		$2.2M Sell
71,775
-2,612
-4% -$57.7K 0.03% 226
2020
Q2 		$1.21M Sell
74,387
-8,003
-10% -$115K 0.02% 283
2020
Q1 		$820K Sell
82,390
-9,601
-10% -$110K 0.01% 314
2019
Q4 		$1.26M Buy
91,991
+1,879
+2% +$27.8K 0.01% 280
2019
Q3 		$1.37M Buy
90,112
+10,184
+13% +$181K 0.01% 255
2019
Q2 		$1.57M Sell
79,928
-11,945
-13% -$198K 0.01% 259
2019
Q1 		$1.52M Buy
91,873
+3,974
+5% +$61.2K 0.01% 259
2018
Q4 		$1.23M Buy
87,899
+20,698
+31% +$274K 0.01% 262
2018
Q3 		$1.18M Buy
67,201
+18,801
+39% +$360K 0.01% 345
2018
Q2 		$881K Buy
48,400
+7,874
+19% +$133K 0.01% 360
2018
Q1 		$760K Buy
40,526
+7,043
+21% +$137K 0.01% 366
2017
Q4 		$512K Buy
+33,483
New +$493K ﹤0.01% 532

Other funds holding KURA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return

ALPS Advisors's KURA Position: Q2 2026 in Review

ALPS Advisors increased its Kura Oncology (KURA) stake by 25% in Q2 2026, buying an estimated $172K and bringing the position to 90,093 shares worth $988K. The position accounts for ﹤0.01% of the portfolio, ranked #707.

ALPS Advisors first reported a position in KURA in Q4 2017 and has held it in 27 quarters since. The position peaked at $2.2M in Q3 2020. 221 funds tracked by Wall St. Rank hold KURA as of Q2 2026.

  • ALPS Advisors held 90,093 shares of Kura Oncology worth $988K as of Q2 2026.
  • ALPS Advisors bought 18,187 Kura Oncology shares in Q2 2026, an estimated $172K.
  • Kura Oncology made up ﹤0.01% of ALPS Advisors's portfolio in Q2 2026, its #707 holding.
  • ALPS Advisors first reported a position in Kura Oncology in Q4 2017 and has held it in 27 quarters since.
  • ALPS Advisors's Kura Oncology position peaked at $2.2M in Q3 2020.
  • 221 funds tracked by Wall St. Rank held Kura Oncology as of Q2 2026.

Based on ALPS Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.